Aubagio

Is Aubagio still ethical to use as comparator in MS trials?

Noting that Aubagio (teriflunomide) continues to have “a robust impact on disability progression” in multiple sclerosis (MS) despite being eclipsed by newer MS treatments in trials, an international team of researchers are now arguing that it is, in fact, still ethical to use the older therapy as a…

Aubagio shifts immune cell balance in RRMS, study reveals

Aubagio (teriflunomide), an approved therapy for relapsing forms of multiple sclerosis (MS), works by shifting the balance between activated subsets of nerve-damaging immune cells to those with immunosuppressive traits, a new study reveals. Further studies to understand how changes in immune cell subsets drive Aubagio’s clinical effectiveness will…

Aubagio Significantly Lowers Plasma NfL Levels in TERIKIDS Trial

Aubagio (teriflunomide) can significantly reduce plasma neurofilament light chain (pNfL) levels, a biomarker of nerve cell damage, in children and adolescents with relapsing-remitting multiple sclerosis (RRMS). That’s according to a new analysis of data from TERIKIDS (NCT02201108), the Phase 3 trial that supported expanding Aubagio’s indication in…

#AAN2022 – Ublituximab Bests Aubagio on Disability Measures

Ublituximab, an experimental therapy for relapsing multiple sclerosis (MS) patients, outperformed Aubagio on a number of disability-related outcomes in the ULTIMATE clinical trials, new data show. The findings were presented in a series of posters at the 2022 American Academy of Neurology (AAN) Annual Meeting, being held in…

Ublituximab as Relapsing MS Therapy Under FDA Review

The U.S. Food and Drug Administration (FDA) has agreed to review TG Therapeutics’ application seeking the approval of ublituximab as a treatment for people with relapsing forms of multiple sclerosis. An FDA’s decision is expected on or before Sept. 28. The agency is not currently planning to hold an…

Report: Tecfidera, Aubagio Preferred RRMS Treatments in Canada

Tecfidera (dimethyl fumarate) and Aubagio (teriflunomide) are the preferred disease-modifying treatments for managing relapsing-remitting multiple sclerosis (RRMS) in Canada, according to a report from Spherix Global Insights. The report was part of Spherix’s RealTime Dynamix: Multiple Sclerosis (Canada) service, which collects data on market trends of MS…

Tecfidera May Reduce Relapse Rate More Than Other RRMS Therapies

First-line treatment with Tecfidera (dimethyl fumarate) leads to a lower rate of relapses in people with relapsing-remitting multiple sclerosis (RRMS) than does treatment with Aubagio (teriflunomide) or injectable immunomodulators, according to an analysis of insurance data from France. “These data will be useful to feed into physician…

Oral Aubagio Approved in EU for Children With RRMS, Ages 10-17

The European Commission (EC) has approved Aubagio (teriflunomide) for the treatment of children and adolescents, ages 10 to 17, with relapsing-remitting multiple sclerosis (RRMS). Aubagio, approved for adults with RRMS since 2013, is now the first oral therapy available as a first-line treatment for pediatric patients in the European…

Results: Ponvory Outperforms Aubagio in OPTIMUM Clinical Trial

In the OPTIMUM clinical trial, Ponvory (ponesimod) significantly outperformed Aubagio (teriflunomide) in reducing relapse rates, fatigue, and evidence of brain damage among people with relapsing multiple sclerosis (MS). Based on these results, Ponvory has now been approved in the U.S. and the European Union as a treatment…

FDA Rejects Expansion of Aubagio for Pediatric MS

The U.S. Food and Drug Administration (FDA) has rejected an application requesting the expansion of Aubagio (teriflunomide) for the treatment of children and adolescents, ages 10 to 17, with relapsing forms of multiple sclerosis (MS). “The FDA deemed the data submitted were not sufficient to obtain approval of…

Ponvory Approved in EU for Active Relapsing Forms of MS

The European Commission has approved Ponvory (ponesimod) to treat adults with relapsing forms of multiple sclerosis (MS) and active disease, as defined by clinical or imaging features. The approval, which follows a recommendation from the Committee for Medicinal Products for Human Use in March, covers clinically isolated…